• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于在HEK 293补料分批培养中高滴度生产腺病毒载体的培养基和补料策略优化

Optimization of Culture Media and Feeding Strategy for High Titer Production of an Adenoviral Vector in HEK 293 Fed-Batch Culture.

作者信息

Shen Chun Fang, Rodenbrock Anja, Lanthier Stephane, Burney Elodie, Loignon Martin

机构信息

Human Health Therapeutics Research Centre, National Research Council of Canada, Montreal, QC H4P 2R2, Canada.

出版信息

Vaccines (Basel). 2024 May 10;12(5):524. doi: 10.3390/vaccines12050524.

DOI:10.3390/vaccines12050524
PMID:38793775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11125598/
Abstract

Adenoviruses are efficient and safe vectors for delivering target antigens and adenovirus-based vaccines have been used against a wide variety of pathogens, including tuberculosis and COVID-19. Cost-effective and scalable biomanufacturing processes are critical for the commercialization of adenovirus-vectored vaccines. Adenoviral vectors are commonly produced through the infection of batch cultures at low cell density cultures, mostly because infections at high cell densities result in reduced cell-specific virus productivity and does not improve volumetric productivity. In this study, we have investigated the feasibility of improving the volumetric productivity by infecting fed-batch cultures at high cell densities. Four commercial and one in-house developed serum-free media were first tested for supporting growth of HEK 293 cells and production of adenovirus type 5 (Ad5) in batch culture. Two best media were then selected for development of fed-batch culture to improve cell growth and virus productivity. A maximum viable cell density up to 16 × 10 cells/mL was achieved in shake flask fed-batch cultures using the selected media and commercial or in-house developed feeds. The volumetric virus productivity was improved by up to six folds, reaching 3.0 × 10 total viral particles/mL in the fed-batch culture cultivated with the media and feeds developed in house and infected at a cell density of 5 × 10 cells/mL. Additional rounds of optimization of media and feed were required to maintain the improved titer when the fed-batch culture was scaled up in a bench scale (3 L) bioreactor. Overall, the results suggested that fed-batch culture is a simple and feasible process to significantly improve the volumetric productivity of Ad5 through optimization and balance of nutrients in culture media and feeds.

摘要

腺病毒是递送靶抗原的高效且安全的载体,基于腺病毒的疫苗已被用于对抗多种病原体,包括结核病和新冠病毒。具有成本效益且可扩展的生物制造工艺对于腺病毒载体疫苗的商业化至关重要。腺病毒载体通常通过在低细胞密度培养物中感染分批培养物来生产,主要是因为在高细胞密度下感染会导致细胞特异性病毒生产力降低,并且不会提高体积生产力。在本研究中,我们研究了通过在高细胞密度下感染补料分批培养物来提高体积生产力的可行性。首先测试了四种市售和一种内部开发的无血清培养基,以支持HEK 293细胞的生长和在分批培养中生产5型腺病毒(Ad5)。然后选择两种最佳培养基来开发补料分批培养物,以改善细胞生长和病毒生产力。使用选定的培养基和市售或内部开发的补料,在摇瓶补料分批培养物中实现了高达16×10个细胞/mL的最大活细胞密度。体积病毒生产力提高了多达六倍,在用内部开发的培养基和补料培养并在细胞密度为5×10个细胞/mL时感染的补料分批培养物中达到3.0×10个总病毒颗粒/mL。当补料分批培养物在实验室规模(3 L)生物反应器中放大时,需要进一步优化培养基和补料以维持提高的滴度。总体而言,结果表明补料分批培养是一种简单可行的方法,通过优化和平衡培养基和补料中的营养成分,可以显著提高Ad5的体积生产力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/1fdbbeaca84f/vaccines-12-00524-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/e0fac45f22c1/vaccines-12-00524-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/39a9a3621902/vaccines-12-00524-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/2548676eb0dd/vaccines-12-00524-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/39cbe6450ea0/vaccines-12-00524-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/453dbe4c32fa/vaccines-12-00524-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/04a48fc7677c/vaccines-12-00524-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/1fdbbeaca84f/vaccines-12-00524-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/e0fac45f22c1/vaccines-12-00524-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/39a9a3621902/vaccines-12-00524-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/2548676eb0dd/vaccines-12-00524-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/39cbe6450ea0/vaccines-12-00524-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/453dbe4c32fa/vaccines-12-00524-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/04a48fc7677c/vaccines-12-00524-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1737/11125598/1fdbbeaca84f/vaccines-12-00524-g007.jpg

相似文献

1
Optimization of Culture Media and Feeding Strategy for High Titer Production of an Adenoviral Vector in HEK 293 Fed-Batch Culture.用于在HEK 293补料分批培养中高滴度生产腺病毒载体的培养基和补料策略优化
Vaccines (Basel). 2024 May 10;12(5):524. doi: 10.3390/vaccines12050524.
2
Low-glutamine fed-batch cultures of 293-HEK serum-free suspension cells for adenovirus production.用于腺病毒生产的293-HEK无血清悬浮细胞的低谷氨酰胺补料分批培养。
Biotechnol Prog. 2003 Mar-Apr;19(2):501-9. doi: 10.1021/bp025638o.
3
Culture media selection and feeding strategy for high titer production of a lentiviral vector by stable producer clones cultivated at high cell density.高细胞密度培养的稳定生产克隆生产高滴度慢病毒载体的培养基选择和喂养策略。
Bioprocess Biosyst Eng. 2022 Aug;45(8):1267-1280. doi: 10.1007/s00449-022-02737-5. Epub 2022 Jun 27.
4
Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate.用于生产腺病毒载体结核疫苗候选物的细胞培养和纯化工艺的优化与放大
Vaccine. 2016 Jun 17;34(29):3381-7. doi: 10.1016/j.vaccine.2016.04.090. Epub 2016 May 4.
5
Automated dynamic fed-batch process and media optimization for high productivity cell culture process development.自动化动态流加批次工艺和培养基优化用于高生产力细胞培养工艺开发。
Biotechnol Bioeng. 2013 Jan;110(1):191-205. doi: 10.1002/bit.24602. Epub 2012 Sep 1.
6
High-cell-density cultivations to increase MVA virus production.提高 MVA 病毒产量的高密度细胞培养。
Vaccine. 2018 May 24;36(22):3124-3133. doi: 10.1016/j.vaccine.2017.10.112. Epub 2018 Feb 9.
7
Insights into adenoviral vector production kinetics in acoustic filter-based perfusion cultures.基于声学过滤器的灌注培养中腺病毒载体生产动力学的见解
Biotechnol Bioeng. 2004 Jun 30;86(7):765-74. doi: 10.1002/bit.20074.
8
Bioreactor productivity and media cost comparison for different intensified cell culture processes.不同强化细胞培养工艺的生物反应器生产力与培养基成本比较
Biotechnol Prog. 2017 Jul;33(4):867-878. doi: 10.1002/btpr.2415. Epub 2017 Jan 28.
9
High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.使用 ATF 系统的杂交补料分批/灌注策略生产高滴度 MVA 和流感 A 病毒。
Appl Microbiol Biotechnol. 2019 Apr;103(7):3025-3035. doi: 10.1007/s00253-019-09694-2. Epub 2019 Feb 23.
10
Process intensification to produce a difficult-to-express therapeutic enzyme by high cell density perfusion or enhanced fed-batch.通过高密度灌注或强化补料分批培养来实现生产表达困难的治疗性酶的过程强化。
Biotechnol Bioeng. 2021 Sep;118(9):3533-3544. doi: 10.1002/bit.27806. Epub 2021 May 13.

本文引用的文献

1
Development, optimization, and scale-up of suspension Vero cell culture process for high titer production of oncolytic herpes simplex virus-1.悬浮 Vero 细胞培养工艺的开发、优化和放大,用于高滴度的溶瘤单纯疱疹病毒-1 的生产。
Biotechnol J. 2024 Jan;19(1):e2300244. doi: 10.1002/biot.202300244. Epub 2023 Oct 15.
2
Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy.腺病毒疗法递送交叉杂交IgGA Fc工程化PD-L1抑制剂以增强癌症免疫治疗。
Mol Ther Oncolytics. 2023 May 20;29:125-126. doi: 10.1016/j.omto.2023.05.001. eCollection 2023 Jun 15.
3
Rapid-response manufacturing of adenovirus-vectored vaccines.
腺病毒载体疫苗的快速响应制造。
Nat Biotechnol. 2023 Mar;41(3):314-316. doi: 10.1038/s41587-023-01682-2.
4
Culture media selection and feeding strategy for high titer production of a lentiviral vector by stable producer clones cultivated at high cell density.高细胞密度培养的稳定生产克隆生产高滴度慢病毒载体的培养基选择和喂养策略。
Bioprocess Biosyst Eng. 2022 Aug;45(8):1267-1280. doi: 10.1007/s00449-022-02737-5. Epub 2022 Jun 27.
5
Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production.用于无血清腺病毒载体带状疱疹疫苗生产的灌注工艺开发。
AMB Express. 2022 May 14;12(1):58. doi: 10.1186/s13568-022-01398-7.
6
Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens.腺病毒载体疫苗——新兴病毒病原体大流行防范的平台。
Mol Ther. 2022 May 4;30(5):1822-1849. doi: 10.1016/j.ymthe.2022.01.034. Epub 2022 Jan 31.
7
Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.基于腺病毒载体的平台,用于开发有效的疫苗以对抗呼吸道病毒感染。
Clin Transl Immunology. 2021 Oct 12;10(10):e1345. doi: 10.1002/cti2.1345. eCollection 2021.
8
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.制造一种黑猩猩腺病毒载体的新冠病毒疫苗以满足全球需求。
Biotechnol Bioeng. 2022 Jan;119(1):48-58. doi: 10.1002/bit.27945. Epub 2021 Nov 15.
9
Cell culture-based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system.基于细胞培养的、使用交变切向流过滤系统在灌注模式下生产缺陷干扰性流感 A 病毒颗粒。
Appl Microbiol Biotechnol. 2021 Oct;105(19):7251-7264. doi: 10.1007/s00253-021-11561-y. Epub 2021 Sep 14.
10
A Different Perspective: How Much Innovation Is Really Needed for Monoclonal Antibody Production Using Mammalian Cell Technology?一种不同的视角:使用哺乳动物细胞技术生产单克隆抗体究竟需要多少创新?
Adv Biochem Eng Biotechnol. 2018;165:443-462. doi: 10.1007/10_2018_59.